Construction and application of double-transfected cells expressing the human transporter P-glycoprotein and cytochrome P450 3A4.

H H Hu, C Su, Yutian Jiang, Lei Yu, Y Liu, Yanzhang Tian, Siyun Xu, Hou‐De Zhou, Xinrong He, Hongbin Jiang, Shaohua ZengPubMed 2013

TL;DR

This paper presents a novel double-transfected cell line (MDCK-MDR1/CYP3A4) that co-expresses P-glycoprotein (P-gp) and Cytochrome P450 3A4 (CYP3A4). This model effectively mimics the combined drug efflux and metabolic barrier found in the human intestine, allowing for a more accurate study of drug disposition and detoxification.

What Problem Does This Paper Address?

The human intestine acts as a significant barrier to drug absorption and can also metabolize drugs before they reach systemic circulation. This barrier is formed by two key players: P-glycoprotein (P-gp), an efflux transporter that pumps drugs back into the intestinal lumen, and Cytochrome P450 3A4 (CYP3A4), a major metabolic enzyme that breaks down drugs. Understanding how these two systems interact is crucial for predicting drug bioavailability, efficacy, and potential toxicity. Previous in vitro models often studied these components separately or in cell lines with other confounding transporters. This paper aims to create a more refined in vitro model that specifically captures the synergistic interplay between P-gp and CYP3A4 in drug detoxification.

Methods

The researchers constructed two cell lines: a single-transfected line expressing CYP3A4 (MDCK-CYP3A4) and a double-transfected line co-expressing both P-gp and CYP3A4 (MDCK-MDR1/CYP3A4). They utilized recombinant plasmids (pcDNA3.1/Hypgro/CYP3A4) for transfection into MDCK and MDCK-MDR1 cells.

Key techniques employed include:

  • Plasmid Construction and Verification: Standard molecular biology techniques like restriction enzyme digestion and DNA sequencing were used to construct and confirm the integrity of the CYP3A4 gene construct.
  • Cell Transfection and Selection: Lipofectamine™ LTX was used for transfection, followed by selection using Hygro B to isolate stable cell lines.
  • Protein Expression Analysis: Western blotting was used to confirm the presence and expression levels of CYP3A4 protein in the transfected cells.
  • Enzyme Activity Assays:
    • Fluorescence-based assay: Using 7-benzyloxy-4-trifluoromethylcoumarin (BFC) as a substrate to measure CYP3A4 activity by detecting its metabolite (7-HFC).
  • P450 Glo™ CYP3A4 Assay: A highly sensitive luminescent assay using a luciferin-IPA substrate.
  • HPLC and LC-MS/MS: For quantitative analysis of CYP3A4-mediated metabolism of classic substrates like testosterone (6ẞ-hydroxylation) and midazolam (1-hydroxylation).
  • Cytotoxicity Assay (MTT): To assess the impact of P-gp and CYP3A4 on the toxicity of a known substrate, paclitaxel, by measuring cell viability and determining IC50 values.

Datasets

Not discussed in the paper. The study relies on established cell lines (MDCK, MDCK-MDR1) and uses commercially available reagents and substrates for experimental assays.

Key Insights and Ideas

  • Synergistic Detoxification: The most striking insight is the dramatic decrease in paclitaxel toxicity in the double-transfected MDCK-MDR1/CYP3A4 cells compared to single-transfected cells. This strongly suggests a cooperative effect where P-gp efflux and CYP3A4 metabolism work together to reduce cellular drug exposure and damage.
  • Refined In Vitro Model: The developed double-transfected cell line serves as a more physiologically relevant model for studying drug disposition in the intestine, overcoming limitations of previous models that might have included other transporters or lacked specific CYP3A4 expression.
  • Interplay is Key: The study provides experimental evidence for the hypothesized interplay between P-gp and CYP3A4, moving beyond theoretical discussions to demonstrate its functional consequences on drug toxicity.

Key Results

  • Successful Construction: The researchers successfully constructed and verified single-transfected (MDCK-CYP3A4) and double-transfected (MDCK-MDR1/CYP3A4) cell lines.
  • CYP3A4 Expression and Activity: Western blot confirmed CYP3A4 protein expression, and various assays demonstrated functional CYP3A4 activity in the transfected cells, with specific monoclones showing high activity.
  • Paclitaxel Toxicity Reduction:
    • In MDCK-MDR1 cells, paclitaxel toxicity was reduced due to P-gp efflux (higher IC50).
  • In MDCK-CYP3A4 cells, toxicity was reduced due to CYP3A4 metabolism (higher IC50).
  • In MDCK-MDR1/CYP3A4 cells, paclitaxel toxicity was dramatically reduced, indicating a significant synergistic effect. The IC50 values for paclitaxel were: MDCK (0.04 µM), MDCK-CYP3A4 (0.08 µM), MDCK-MDR1 (0.11 µM), and MDCK-MDR1/CYP3A4 (0.18 µM).

Limitations and Future Work

  • Limitations:
    • The study primarily focuses on paclitaxel as a model substrate. While it demonstrates the principle, further validation with a broader range of CYP3A4/P-gp substrates would strengthen the findings.
  • The cell model is derived from MDCK cells, which are kidney epithelial cells, not intestinal cells. While they express the key proteins, the overall cellular context might differ from native intestinal enterocytes.
  • The paper mentions "preliminarily determined" interaction, suggesting further in-depth studies are needed.
  • Future Work:
    • The authors suggest that this cell model can be applied to study the toxicity and detoxification of various chemicals due to the combined action of CYP3A4 metabolism and P-gp efflux.
  • Further investigation into the precise molecular mechanisms of the interplay between P-gp and CYP3A4 is warranted.
  • Exploring the application of this model to predict drug-drug interactions involving CYP3A4 inhibitors/inducers and P-gp substrates would be a valuable next step.

Summary updated

Abstract

Intestinal P-glycoprotein (P-gp) and cytochrome P450 (CYP) enzymes are known to influence oral bioavailabilities of drugs. Recombinant plasmids pcDNA3.1/Hypgro/CYP3A4 were transfected into MDCK and MDCK-MDR1 cells to construct the single-transfected cell line MDCK-CYP3A4 and double-transfected cell line MDCK-MDR1/CYP3A4. The expression of CYP3A4 in the double-transfected cell line was determined by Western blot and its activity was detected by the metabolism assays of three substrates of CYP3A4, which were 7-benzyloxy-4-trifluoro-methylcoumarin (BFC), testosterone and midazolam. In addition, the selection of monoclones with high CYP3A4 activities in the single-tranfected cell line was performed by the P450 Glo CYP3A4 assay. Through MTT assay, the interaction between P-gp and CYP3A4 was preliminarily determined based on the changes of IC50 values. The results showed that paclitaxel detoxified in the single-transfected MDCK-MDR1 cell because of P-gp efflux. And it was also less toxic in the single-transfected CYP3A4 cell line due to the metabolism by CYP3A4. In the double-transfected MDCK-MDR1/CYP3A4 cell line, the toxicity decreased dramatically because of the interplay between P-gp and CYP3A4. Therefore, the cell model could be applied to study the toxicity and detoxification of chemicals due to the metabolism by CYP3A4 and the efflux through P-gp.
BibTeX
@inproceedings{hu2013construction,
  author = {H H Hu and C Su and Yutian Jiang and Lei Yu and Y Liu and Yanzhang Tian and Siyun Xu and Hou‐De Zhou and Xinrong He and Hongbin Jiang and Shaohua Zeng},
  title = {{Construction and application of double-transfected cells expressing the human transporter P-glycoprotein and cytochrome P450 3A4.}},
  booktitle = {PubMed},
  year = {2013},
}
Figure